Li et al., 2020 - Google Patents
Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivoLi et al., 2020
View PDF- Document ID
- 13244529284788108276
- Author
- Li Z
- Lang Y
- Sakamuru S
- Samrat S
- Trudeau N
- Kuo L
- Rugenstein N
- Tharappel A
- D'Brant L
- Koetzner C
- Hu S
- Zhang J
- Huang R
- Kramer L
- Butler D
- Xia M
- Li H
- Publication year
- Publication venue
- Emerging Microbes & Infections
External Links
Snippet
Many flaviviruses including the Dengue virus (DENV), Zika virus (ZIKV), West Nile virus, Yellow Fever virus, and Japanese encephalitis virus are significant human pathogens, unfortunately without any specific therapy. Here, we demonstrate that methylene blue, an …
- 229940042115 Methylene blue 0 title abstract description 197
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
- C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
- C12N2770/24011—Flaviviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo | |
| Barrows et al. | Biochemistry and molecular biology of flaviviruses | |
| Ulrich et al. | Dengue fever, COVID‐19 (SARS‐CoV‐2), and antibody‐dependent enhancement (ADE): a perspective | |
| Khan et al. | Dengue overview: An updated systemic review | |
| Shan et al. | A Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and fitness for transmission | |
| Chen et al. | Antiviral activity of lycorine against Zika virus in vivo and in vitro | |
| Li et al. | Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease | |
| Mishra et al. | Molecular recognition features in Zika virus proteome | |
| Ke et al. | Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro | |
| Thompson et al. | A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes | |
| Troupin et al. | A role for human skin mast cells in dengue virus infection and systemic spread | |
| Lee et al. | Advances in Zika virus–host cell interaction: Current knowledge and future perspectives | |
| Li et al. | JMX0207, a niclosamide derivative with improved pharmacokinetics, suppresses Zika virus infection both in vitro and in vivo | |
| Chen et al. | Cinnamic acid inhibits Zika virus by inhibiting RdRp activity | |
| Oliveira et al. | NS3 and NS5 proteins: important targets for anti-dengue drug design | |
| Hsieh et al. | Highly conserved residues in the helical domain of dengue virus type 1 precursor membrane protein are involved in assembly, precursor membrane (prM) protein cleavage, and entry | |
| Acosta et al. | Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development | |
| Choy et al. | A non-structural 1 protein G53D substitution attenuates a clinically tested live dengue vaccine | |
| Pauli et al. | West nile virus | |
| Park et al. | Potent inhibition of Zika virus replication by aurintricarboxylic acid | |
| Xing et al. | Snake cathelicidin derived peptide inhibits Zika virus infection | |
| Chakrabartty et al. | Comparative overview of emerging RNA viruses: Epidemiology, pathogenesis, diagnosis and current treatment | |
| Vaziri et al. | Zika virus as an emerging arbovirus of international public health concern | |
| Singh et al. | Neurological Manifestations of Perinatal Dengue | |
| Atif et al. | Serotyping of dengue virus from deadly outbreaks of Pakistan |